CLBIO: 2024 saw heavy losses and restructuring, but Corline targets US growth with CHSTM-coated Globe®

About this update from Corline Biomedical Ab

Corline Biomedical reported a sharp revenue decline and significant one-time write-downs in 2024, but positioned itself for US growth with the FDA submission of the CHSTM-coated Globe® catheter and a strategic focus on medical devices. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Corline Biomedical Ab